Imunon (IMNN) Expected to Announce Earnings on Thursday

Imunon (NASDAQ:IMNN) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Imunon to post earnings of ($1.54) per share for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.

Imunon Price Performance

Shares of IMNN opened at $3.22 on Thursday. The business’s 50-day moving average is $3.56 and its 200-day moving average is $4.62. The company has a market capitalization of $9.89 million, a price-to-earnings ratio of -0.33 and a beta of 2.14. Imunon has a fifty-two week low of $2.99 and a fifty-two week high of $41.22.

Wall Street Analysts Forecast Growth

IMNN has been the topic of several research reports. Brookline Capital Acquisition reiterated a “buy” rating on shares of Imunon in a research note on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $232.50.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Imunon stock. Armistice Capital LLC acquired a new stake in Imunon, Inc. (NASDAQ:IMNN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 266,886 shares of the company’s stock, valued at approximately $1,017,000. Armistice Capital LLC owned about 8.69% of Imunon at the end of the most recent quarter. 4.47% of the stock is currently owned by institutional investors and hedge funds.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.